Sunday, 21 February 2016 16:53

Media Articles and PPS

The media and PPS section on CYTX-Investor.com is split up in a few components.

The first category will cover "media classics" -i.e articles that appeared somewhere on the web during the past ten years or so and were not only well written, but also had an understanding of the future potential of Cytori.

The second category is real "classic" and old..LOL  My own Newsletters from the early web publishing days, when a lot of us, were thinking 40$ Stock price relatively fast. At present- February 2016, we have seen 13,5 cents as PPS...the journey to the stars has crashed on mother earth and we are -lets say-regrouping....

The third category will have a few tools for trade- and chart junkies...Confused 

Thats all- have fun reading.

Media Classics - that means, articles which have appeared online at some media outlet, was well written and of interest to Cytori followers

  • The Analyst´s view
    The Analyst´s view On January 24, 2010 Joe Feshbach (picture- here with his wife Cindy) published an article on his Instablog at Seeking Alpha, written by his friend, former investment banker and author of the book "Lost Star of Myth and Time"- Walter Cruttenden. An absolute classic for believers in Cytori technology. Joe was one of those believers and after attending the first Cellsociety annual meeting in San Diego in February 2011 decided with his brother Matt and other investors, to put his money where his "believes" were and started to organize the construction of a cardiac clinic on the Bahama´s using Cytori tech- i.e.Celution One. Unfortunately Joe suffered a massive heart attack on August 8 2011 whilst on a biketrip and never could see his plans come to fruition.   
    Written on Friday, 13 April 2012 11:33 in Media "Classics" Be the first to comment! Read more...
  • A Conversation with Chris Calhoun
    A Conversation with Chris Calhoun Written by Daniel Fromson Cytori Therapeutics probably ranks somewhere near the top of any list of the world's most innovative medical technology companies--or at least a list of its boldest. As CEO Christopher J. Calhoun explains, the company aims to do nothing less than revolutionize health care by leading the way into an era of regenerative medicine, in which damage from cancer, heart disease, and a host of other ailments can be healed with the body's own cells. The process relies on naturally occurring regenerative cells. "What we have done," Calhoun says, "is developed products that allow a doctor to take a small amount of fat, the same volume as about half a can of Coke
    Written on Friday, 13 April 2012 06:45 in Media "Classics" Be the first to comment! Read more...
  • Sharon Begley´s "Wired" Part I
    Sharon Begley´s "Wired" Part I On this spring afternoon, the 44-year-old CEO of San Diego- based biotech company Cytori Therapeutics pulls out his laptop, launches a PowerPoint presentation, and there they are: conical and cantaloupy. As through Ds, beige and pink and taupe and tan, more breasts than you might see in a women's locker room, never mind in the middle of a lunch table. A passing waiter does a double take at this lively slide show, but Calhoun is oblivi­ous. He's talking excitedly about how these women's bodies led him and his team of sci­entists to a discovery in tissue engineer­ing, a process that could well be one of the most momentous medical advances of the 21st century: the use of stemcells..... specifically stem-cell enriched adipose (fat) tissue—to enhance, heal, and rebuild injured or damaged organs.
    Written on Thursday, 12 April 2012 14:05 in Media "Classics" Be the first to comment! Read more...
  • Sharon Begley´s "Wired"- Part II
    Sharon Begley´s "Wired"- Part II Part II- "These things have gone through the ringer in choosing a name," says biomechan-ical engineer Kent Leach of UC Davis, who has used whatever-they-are to treat bone cysts in racehorses. A stem cell, by definition, is able to differentiate into any of the 200-plus kinds of cells in the human body, just as the cells of a days-old embryo can (and do). Cytori's are unlikely to ever show that range of differentiation. But they can differentiate into fat, bone, and muscle -among other tissues—depending on which signaling molecules they are exposed to. In a petri dish, the scientists provide those "this is what you will be when you grow up" molecules. In nature—that is, an embryo in a womb—biology somehow does.
    Written on Thursday, 12 April 2012 14:42 in Media "Classics" Be the first to comment! Read more...
  • Sign-on SD: Stem Cells from Fat
    Sign-on SD: Stem Cells from Fat San Diego's Cytori banks on a new process to help damaged hearts Getting rid of that spare tire around your middle could help your heart in more ways than you might expect, according to a San Diego biotechnology company. Cytori Therapeutics has developed a machine that pulls stem cells and other regenerative cells out of fat so they can be re-injected into the body to repair tissue damaged by heart attack or disease. Several studies, including some in which Cytori scientists have participated, have shown that stem cells and other regenerative material from fat can help build blood supply and restore blood flow to cardiac muscle that has been damaged by a heart attack.
    Written on Saturday, 14 April 2012 16:45 in Media "Classics"
    Tags: CYTX
    Be the first to comment! Read more...
  • CYTX: a Low Risk Stem Cell Play
    CYTX: a Low Risk Stem Cell Play The biotech company has had successful clinical trials yet is unloved by the market. Here's why investors should start a position now. Written by James Anderson Typically, early-stage biotech companies are considered to have a binary outcome. If successful with the first product that enters clinical trials the company moves on to raise more money through stock sales, enter a partnership with a large pharmaceutical company, or sell the company. In each case, investors do well. However, if the first product fails in its clinical trial, there is a good chance the company will run out of money and fail. Hence, it’s binary -- all or nothing. Stem cell therapies have been garnering significant attention as the field of regenerative medicine starts to evolve. As one would expect, there are a number of start-up biotech companies in the field.
    Written on Tuesday, 17 April 2012 06:50 in Media "Classics" Be the first to comment! Read more...
  • Bioworld- Cytori Fattens Its Coffers
    Bioworld- Cytori Fattens Its Coffers   I found this article in my mailbox yesterday, which appeared on the respected BioWorld Daily Biopharmaceutical News Site, written by Mr. R. Osborne. I think it has some positive statements, which other Cytori shareholders should also be able to take note of-   Cytori Fattens Coffers: $18.5M for Adipose Stem Cell Efforts BioWorld Today By Randy Osborne 17 December 2012   “About $18.5 million in net proceeds from a public offering by Cytori Therapeutics Inc. will go toward boosting the Celution System for processing adipose-derived regenerative cells (ADRCs), as well as clinical trials and general corporate purposes, the company said.   Cytori, of San Diego, sold about 7 million shares of common stock at $2.85 each, and granted underwriters an option to buy about 1 million more.  The new money strengthens not only Cytori's balance sheet but also its position in negotiations, as they continue with would-be strategic partners, said CEO Christopher Calhoun.   He acknowledged "some anxiety" among investors about the promised alliances, but said plans remain active. "We're working on those," he said. "We've got a couple at the late stage, the contract stage. These deals are still coming.  
    Written on Tuesday, 18 December 2012 11:55 in Media "Classics" Be the first to comment! Read more...
  • Jason dines with prominent SC cardiologists
    Jason dines with prominent SC cardiologists   My mailbox has been overflowing off-late with messages of unhappy investors in the Cytori stock. A few days ago, however there was finally a message again with an attachment, that was very positive and worth sharing with the other folks. The report by Jason Kolbert of Maxim´s of his dinner meeting with some leading cardiologists in San Francisco was very interesting. As a fatman, I didnt like his joke very much, but than again- that is of no relevance. Key thing is, that Jason is making great strides in gaining knowledge on the Cell Therapy Industry. Only recently- in August 2012 he displayed his ignorance during the Cytori Conference Call, but has immensely accellerated his knowledge base. Well done Jason- good report- so here you go- just a teaser- if you want to read more of the 26 page report, call Jason at Maxim´s- 212-895-3516.
    Written on Sunday, 23 December 2012 13:27 in Media "Classics"
    Tags: Future
    Be the first to comment! Read more...
Cytx-investor.com- The page for cytori Investors
Last modified on Saturday, 11 June 2016 08:10

Comments (0)

There are no comments posted here yet

Leave your comments

Posting comment as a guest. Sign up or login to your account.
Attachments (0 / 3)
Share Your Location

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites